Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03805594 trial: what clinicians have said so far
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- NCT03805594 ↗
- Completed
- University of California, San Francisco
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03805594 (177Lu-PSMA-617 plus pembrolizumab in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03805594 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer; Stage IVA Prostate Cancer; Stage IVB Prostate Cancer
- Interventions
- Lutetium Lu 177-PSMA-617; Pembrolizumab
- Arms
- Part A: Dosing Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab) · Experimental
- Part A: Dosing Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab) · Experimental
- Part A: Dosing Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab) · Experimental
- Part B: Recommended Phase 2 Dosing Schedule (RP2DS) (lutetium Lu 177-PSMA-617, pembrolizumab) · Experimental
- Enrollment
- 43
- Primary outcomes
- Number of Reported Dose Limiting Toxicities (DLT) (Part A Only)
- Objective Response Rate (ORR) (Part B Only)
- Sponsor
- University of California, San Francisco with Prostate Cancer Foundation, National Cancer Institute (NCI)
- Start
- May 10, 2019
- Primary completion
- Jan 10, 2024
- Results posted
- Yes
- Registry record
- NCT03805594 · updated Feb 25, 2025
Publications
linked from the registry- Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 Nov;24(11):1266-1276. doi: 10.1016/S1470-2045(23)00451-5. PubMed 37922930